{
  "symbol": "BIIB",
  "name": "Biogen",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "2003-11-13",
  "headquarters": "Cambridge, Massachusetts",
  "founded": "1978",
  "market_cap": 19385.655296,
  "pe_ratio": 13.073123,
  "forward_pe": 7.941177,
  "eps": 10.12,
  "revenue": 9816.399872,
  "profit_margin": 0.1507,
  "debt_to_equity": 38.997,
  "return_on_equity": 0.09191,
  "dividend_yield": null,
  "current_price": 132.3000030517578,
  "year_high": 238.0,
  "year_low": 110.04000091552734,
  "price_change_1d": -1.6064283461668223,
  "price_change_1w": 1.714458062557395,
  "price_change_1m": 1.4881884261453426,
  "description": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offer",
  "website": "https://www.biogen.com",
  "employees": 7605,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 172.20387,
  "recommendation": 2.16216,
  "number_of_analysts": 31,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 260.0,
    "target_low": 115.0,
    "target_mean": 172.20387,
    "target_median": 165.0
  },
  "last_updated": "2025-07-09T11:17:46.339094",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}